181 related articles for article (PubMed ID: 36074798)
1. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.
Yu T; Cai QQ; Zhai QL; Li L; Fang X; Li J; Sun R; Yang H; Wang Z; Qian W; Xu-Monette ZY; Young KH; Yu L
Leuk Lymphoma; 2022 Dec; 63(13):3082-3091. PubMed ID: 36074798
[TBL] [Abstract][Full Text] [Related]
2. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
4. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
5. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
6. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.
Liu W; Cai Q; Yu T; Strati P; Hagemeister FB; Zhai Q; Zhang M; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Oksenhendler E; Xu-Monette ZY; Young KH; Yu L
Am J Cancer Res; 2022; 12(9):4227-4240. PubMed ID: 36225639
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
[TBL] [Abstract][Full Text] [Related]
9. The full spectrum of Castleman disease: 273 patients studied over 20 years.
Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 65 patients with Castleman disease in a single center in China.
Wang XQ; Zhong NN; Sun Q; Yan SC; Xu GC; Wang YG; Peng LW; Liu B; Bu LL
Sci Rep; 2022 May; 12(1):8694. PubMed ID: 35610300
[TBL] [Abstract][Full Text] [Related]
11. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Castleman Disease.
Simpson D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
[TBL] [Abstract][Full Text] [Related]
14. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
[TBL] [Abstract][Full Text] [Related]
15. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.
Zhang X; Rao H; Xu X; Li Z; Liao B; Wu H; Li M; Tong X; Li J; Cai Q
Cancer Sci; 2018 Jan; 109(1):199-206. PubMed ID: 29124835
[TBL] [Abstract][Full Text] [Related]
17. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
18. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
Okamoto S
Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.
Qian S; Ding M; Hou H; Wang Z; Zhang J; Zhang Y; Dong M; Zhu L; Wang G; Li W; Zhang X
Front Immunol; 2022; 13():899073. PubMed ID: 35655778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]